Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Cancer: early-phase trial registry
73 of 151 indexed Cervical Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #76 of 28,707 conditions by registered trial count.
151 US clinical trials · 73 currently recruiting · #76 of 28,707 conditions by registered trial count
Cervical Cancer: 151 US clinical trials tracked, 73 recruiting.
Cervical Cancer is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition cervical-cancer
OPEN 73 | RECR 48% | LATE 8 | EARLY 78 | RANK #76 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Chronic Graft Versus Host Disease (48% recruiting · 31 trials)
Cervical Cancer lists 73 open slots (48% of 151 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cervical Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cervical Cancer is recruiting above its size-band peers.
73 of 151 indexed trials (48.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cervical Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 11 of 151 trials (7.3%). 101 distinct sponsors appear on at least one study for this condition label.
-
Typical Cervical Cancer enrolment sits around 100 participants.
Median target enrolment is 100 among the 145 trials that report a genuine target (sentinel values excluded). 72 of those (49.7%) plan for fewer than 100 participants.
-
Cervical Cancer research is mostly interventional.
131 interventional and 20 observational studies make up this index (86.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
151 total, page 1 of 4
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
M.D. Anderson Cancer Center
NCT05359016
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
International Agency for Research on Cancer
NCT06042543
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mayo Clinic
NCT05051722
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
University of California, San Diego
NCT06128304
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Merck Sharp & Dohme
NCT07216703
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
GOG Foundation
NCT04831580
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Merck Sharp & Dohme
NCT06459180
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Abramson Cancer Center at Penn Medicine
NCT05952141
Rice Technologies for Cervical Cancer Screening and Diagnosis
M.D. Anderson Cancer Center
NCT05372484
Reducing Urban Cervical Cancer Disparities
Fox Chase Cancer Center
NCT06416150
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
Cervical Cancer Detection Using Optical Spectroscopy
Duke University
NCT00900575
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
GI Innovation
NCT04977453
Pilot Study for Speculum Free Cervical Cancer Screening
Duke University
NCT04107181
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
University of Alabama at Birmingham
NCT04093388
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Northwestern University
NCT05743517
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Study of NEO-201 in Solid Tumors Expansion Cohorts
Precision Biologics
NCT03476681
PopSci CHW4CervixHealth
Thomas Jefferson University
NCT07336134
Mindfulness in Endometrial and Cervical Cancer
St. Louis University
NCT04512144
A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics
NCT05086692
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
AstraZeneca
NCT06535607
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Pfizer
NCT06952660
Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
Northwell Health
NCT05606133
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
ASk Questions in GYnecologic Oncology (ASQ-GYO)
Ira Winer
NCT06339827
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
Medtronic - MITG
NCT07120945
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
University of Utah
NCT05979610
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
NCT07064018
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
Jonsson Comprehensive Cancer Center
NCT06538337
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Washington University School of Medicine
NCT05975593
A Study of VET3-TGI in Patients With Solid Tumors
KaliVir Immunotherapeutics
NCT06444815
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
University of Florida
NCT07214584
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 30 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cervical Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cervical Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cervical Cancer page
151 registered trials, 73 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 73 Cervical Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Cervical Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical Cancer condition card totals 151 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.